SI-BONE’s (SIBN) “Buy” Rating Reiterated at Needham & Company LLC

Needham & Company LLC restated their buy rating on shares of SI-BONE (NASDAQ:SIBN) in a research note published on Monday,Benzinga reports. They currently have a $19.00 price target on the stock.

Separately, Truist Financial raised their price objective on shares of SI-BONE from $16.00 to $18.00 and gave the stock a “buy” rating in a report on Wednesday, November 13th. Six investment analysts have rated the stock with a buy rating, According to data from MarketBeat, the company presently has a consensus rating of “Buy” and an average target price of $23.00.

SI-BONE Trading Up 4.9 %

SIBN stock opened at $16.47 on Monday. The company has a debt-to-equity ratio of 0.22, a current ratio of 8.25 and a quick ratio of 7.22. The firm has a 50 day simple moving average of $13.75 and a 200-day simple moving average of $14.26. SI-BONE has a twelve month low of $11.70 and a twelve month high of $21.64.

Insider Activity

In other SI-BONE news, insider Anthony J. Recupero sold 3,670 shares of the firm’s stock in a transaction dated Thursday, January 2nd. The shares were sold at an average price of $13.90, for a total value of $51,013.00. Following the transaction, the insider now owns 222,814 shares of the company’s stock, valued at $3,097,114.60. This trade represents a 1.62 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is available at this link. Also, CFO Anshul Maheshwari sold 2,439 shares of the company’s stock in a transaction that occurred on Monday, November 18th. The shares were sold at an average price of $12.68, for a total value of $30,926.52. Following the transaction, the chief financial officer now directly owns 194,623 shares of the company’s stock, valued at $2,467,819.64. This trade represents a 1.24 % decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last three months, insiders sold 27,348 shares of company stock valued at $356,349. Company insiders own 3.90% of the company’s stock.

Institutional Investors Weigh In On SI-BONE

A number of hedge funds have recently added to or reduced their stakes in SIBN. Bank of New York Mellon Corp increased its holdings in shares of SI-BONE by 9.4% in the 2nd quarter. Bank of New York Mellon Corp now owns 142,106 shares of the company’s stock worth $1,837,000 after acquiring an additional 12,158 shares during the period. Rhumbline Advisers grew its position in SI-BONE by 1.5% in the 2nd quarter. Rhumbline Advisers now owns 59,419 shares of the company’s stock worth $768,000 after purchasing an additional 852 shares during the last quarter. Arizona State Retirement System increased its stake in shares of SI-BONE by 9.0% in the second quarter. Arizona State Retirement System now owns 10,921 shares of the company’s stock valued at $141,000 after purchasing an additional 903 shares during the period. American Century Companies Inc. raised its holdings in shares of SI-BONE by 22.8% during the second quarter. American Century Companies Inc. now owns 1,986,476 shares of the company’s stock valued at $25,685,000 after buying an additional 368,637 shares during the last quarter. Finally, Divisadero Street Capital Management LP acquired a new position in shares of SI-BONE during the second quarter worth approximately $1,552,000. 98.11% of the stock is currently owned by institutional investors.

SI-BONE Company Profile

SI-BONE, Inc, a medical device company, that operate to solve musculoskeletal disorders of the sacropelvic anatomy in the United States and internationally. It offers proprietary minimally invasive surgical implant system to address sacroiliac joint dysfunction and fusion, adult deformity and degeneration, and pelvic trauma; and implantable bone products.